Lidocaïne Hcl Cf (Lidocaine Hydrochloride)

Lidocaine is employed in clinical settings where rapid nerve impulse blockade is required, particularly for procedures involving the cardiovascular or peripheral nervous systems.

• Minor surgical or diagnostic procedures: provides local anesthesia to numb the targeted area.
• Acute pain management: reduces pain by inhibiting transmission of nerve signals.
• Ventricular arrhythmias: acts as an intravenous antiarrhythmic to stabilize cardiac rhythm.

• Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the rapid influx of sodium ions that initiates and propagates action potentials. By stabilizing the neuronal membrane, it suppresses the generation and conduction of nerve impulses, resulting in loss of sensation in the treated area and, when given intravenously, reduces abnormal cardiac excitability.

Lidocaine may cause a range of adverse reactions, from mild to severe, depending on dose, route, and patient factors.

Common Side Effects

• Tingling or numbness at the injection site.
• Dizziness or light‑headedness.
• Nausea or metallic taste.
• Mild hypotension.
• Localized swelling or erythema.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis) with rash, bronchospasm, or angioedema.
• Cardiac conduction disturbances such as bradycardia, heart block, or ventricular arrhythmias.
• Central nervous system toxicity manifesting as seizures or loss of consciousness.
• Respiratory depression or apnea.
• Methemoglobinemia, a rare blood disorder causing reduced oxygen delivery.

Before using Lidocaïne Hcl Cf, clinicians should consider several safety measures.

• Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics.
• Cardiovascular monitoring: observe for arrhythmias or hypotension during intravenous administration.
• Hepatic function: consider dose reduction in patients with significant liver impairment.
• Concomitant CNS depressants: use with caution as additive central nervous system effects may occur.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocaine can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase risk of cardiac toxicity.
• CYP3A4 inhibitors (e.g., amiodarone, ketoconazole): can raise plasma lidocaine levels, leading to toxicity.
• Other local anesthetics: concurrent use raises cumulative toxicity risk.

Moderate Interactions (Monitor Closely)

• Beta‑blockers (e.g., propranolol): may enhance bradycardic effects.
• CNS depressants (e.g., benzodiazepines, opioids): monitor for additive sedation or respiratory depression.
• CYP1A2 inducers (e.g., rifampin): may reduce lidocaine concentrations, potentially decreasing efficacy.